Vulvar cancer in young woman—case report

Vulvar cancer is rare with incidence of 45,240 new cases globally which account for 4% of all genitourinary tract neoplasma. It is considered as a postmenopausal disease, however incidence age has decreased over the years because of high prevalence of persistent high-risk human papillomavirus (hrHPV) infection. Vulvar cancer diagnosis in young women is challenging. Prompt and adequate diagnosis, and treatment can ensure the life quality. A 23 years old patient was admitted to Department of Operative Gynecology for treating malignant vulvar neoplasma. She was reffered to our clinic for electrocauterization after being diagnosed of condylomata accuminata. Physical examination revealed vulva atrophy with smooth discolored skin patches on both sides. A 2 cm exophytic lesion was noted ~10 mm from clitoris on right labia majora. Multifocal biopsy was performed for suspect finding which proved invasive vulvar squamous keratinizing cancer. Positron emission tomography-computed tomography (PET/CT) scan showed individual lymph nodes on right inguinofemoral region which were moderately metabolically active. Wide excision of cancer was performed with unilateral inguinofemoral lymphadenectomy. Macroscopic evaluation of entire specimen depicted 2.4 × 2.2 × 0.5 cm HPV associated invasive vulvar squamous keratinizing cancer, vulvar high grade squamous intraepithelial lesion (vHSIL) or usual type vulvar intraepithelial neoplasia (uVIN3) and lichen sclerosus. Healthcare professionals in primary care centers should be adequately trained, aware of and familiar with vulvar malignancies in younger women despite their rarity. Early diagnosis can improve outcomes in vulvar cancer via reducing morbidity and mortality. The individualized surgical treatment is the preferred strategy for patients at present.

Vulvar cancer; HPV infection; Young women; Lichen sclerosus

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Butt JL, Botha MH. Vulvar cancer is not a disease of the elderly: treatment and outcome at a tertiary referral centre in South Africa. South African Medical Journal. 2017; 107: 1000–1004.

[3] Hinten F, Molijn A, Eckhardt L, Massuger LFAG, Quint W, Bult P, et al. Vulvar cancer: two pathways with different localization and prognosis. Gynecologic Oncology. 2018; 149: 310–317.

[4] Bornstein J, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl TG, et al. The 2015 international society for the study of vulvovaginal disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. Obstetrics and Gynecology. 2016; 127: 264–268.

[5] Buchanan T, Mutch D. Squamous cell carcinoma of the vulva: a review of present management and future considerations. Expert Review of Anticancer Therapy. 2019; 19: 43–50.

[6] Olawaiye AB, Cotler J, Cuello MA, Bhatla N, Okamoto A, Wilailak S, et al. FIGO staging for carcinoma of the vulva: 2021 revision. International Journal of Gynaecology and Obstetrics. 2021; 155: 43–47.

[7] de Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. European Journal of Cancer. 2013; 49: 3450–3461.

[8] Brinton LA, Thistle JE, Liao LM, Trabert B. Epidemiology of vulvar neoplasia in the NIH-AARP study. Gynecologic Oncology. 2017; 145: 298–304.

[9] Bertoli HK, Thomsen LT, Iftner T, Dehlendorff C, Kjær SK. Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: a population-based prospective cohort study. Gynecologic Oncology. 2020; 157: 456–462.

[10] van de Nieuwenhof HP, Massuger LFAG, van der Avoort IAM, Bekkers RLM, Casparie M, Abma W, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. European Journal of Cancer. 2009; 45: 851–856.

[11] Tran DA, Tan X, Macri CJ, Goldstein AT, Fu SW. Lichen sclerosus: an autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. International Journal of Biological Sciences. 2019; 15: 1429–1439.

[12] Goldstein AT, Marinoff SC, Christopher K, Srodon M. Prevalence of vulvar lichen sclerosus in a general gynecology practice. The Journal of Reproductive Medicine. 2005; 50: 477–80.

[13] Di Saia PJ, Creasman WT. Invasive cancer of the vulva. In Di Saia PJ, Creasman WT. (eds.) Clinical Gynecologic Oncology (pp. 212–241). 6th edn. Mosby: St.Louis. 2002.

[14] Bleeker MCG, Visser PJ, Overbeek LIH, van Beurden M, Berkhof J. Lichen sclerosus: incidence and risk of vulvar squamous cell carcinoma. Cancer Epidemiology, Biomarkers & Prevention. 2016; 25: 1224–1230.

[15] Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, et al. British association of dermatologists guidelines for the management of lichen sclerosus 2018. The British Journal of Dermatology. 2018; 178: 823–824.

[16] Dellinger TH, Hakim AA, Lee SJ, Wakabayashi MT, Morgan RJ, Han ES. Surgical management of vulvar cancer. Journal of the National Comprehensive Cancer Network. 2017; 15: 121–128.

[17] Oonk MHM, Planchamp F, Baldwin P, Bidzinski M, Brännström M, Landoni F, et al. European society of gynaecological oncology guidelines for the management of patients with vulvar cancer. International Journal of Gynecologic Cancer. 2017; 27: 832–837.

[18] Micheletti L, Preti M, Radici G, Boveri S, Di Pumpo O, Privitera SS, et al. Vulvar lichen sclerosus and neoplastic transformation. Journal of Lower Genital Tract Disease. 2016; 20: 180–183.